This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Resources

Ophthalmology HCP Resources

Discover our HCP resources to learn more about EYLEA® (aflibercept) 8 mg

Close-up-eye

Explore the resources outlined below to gain further insights into EYLEA® (aflibercept) 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).1

Post-hoc analyses of the PULSAR and PHOTON data

The summary videos below highlight some of the key findings from the latest post-hoc analyses of the PULSAR (randomised, double-masked, non-inferiority, phase 3 trial in nAMD) 96-week data and the PHOTON (randomised, double-masked, non-inferiority, phase 2/3 trial in DMO) 156-week data.

Post-hoc analysis of the PULSAR fluid free status 96-week data

In this 4-minute summary video, Richard Gale presents the outcomes of fluid free status within the nAMD patient cohort of the PULSAR trial.

Prescribing information for EYLEA® (aflibercept) can be found here.

Clinical papers

The PULSAR and PHOTON 1-Year (48-weeks) primary manuscripts have been published in The Lancet and are now available to download using the links below.2,3

PULSAR

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial2

Access Here

Quick fire cases of EYLEA 8 mg with Dr Kenneth Fan

In this webinar recording, Dr Kenneth Fan discusses 5 patient case studies, sharing his experience of treating both naive and switch patients with nAMD and DMO using EYLEA 8 mg. Dr Fan also answers questions related to EYLEA 8 mg’s safety profile, drying effects and interval extensions.

Prescribing information for EYLEA® (aflibercept) can be found here.

Please refer to the links below to hear from other experts who have used EYLEA 8 mg, and explore a variety of on-demand resources created in collaboration with both local and internationally recognised leaders in medical retina.

Real World Experience
Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
PP-EYL-GB-2790, March 2025
Retinal Pioneers Programme
A source of on-demand, educational resources developed in collaboration with national and international thought leaders
PP-EYL-GB-2803, March 2025
Early Insights Case Study Webinar Series
Key experts in medical retina, from both the UK and the US, discuss their patient cases
PP-EYL-GB-2577, November 2024

Abbreviations

DMO, diabetic macular oedema. HCP, healthcare professional. nAMD, neovascular (wet) age-related macular degeneration.

References

  1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
  2. Lanzetta P, et al. Lancet 2024;403:1141–1152.
  3. Brown DM, et al. Lancet 2024;403:1153–1163.
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2837, May 2025
Ophthalmology Patient Support Materials
Access our range of downloadable patient support booklets and other resources
PP-EYL-GB-2368, August 2024
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-2820 | April 2025